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Abstract
Background: The cellular localization of the α1D-adrenergic receptor (α1D-AR) is controversial.
Studies in heterologous cell systems have shown that this receptor is expressed in intracellular
compartments. Other studies show that dimerization with other ARs promotes the cell surface
expression of the α1D-AR. To assess the cellular localization in vascular smooth muscle cells, we
developed an adenoviral vector for the efficient expression of a GFP labeled α1D-AR. We also
measured cellular localization with immunocytochemistry. Intracellular calcium levels,
measurement of reactive oxygen species and contraction of the rat aorta were used as measures
of functional activity.
Results: The adenovirally expressed α1D-AR was expressed in intracellular compartments in
human aortic smooth muscle cells. The intracellular localization of the α1D-AR was also
demonstrated with immunocytochemistry using an α1D-AR specific antibody. RT-PCR analysis
detected mRNA transcripts corresponding to the α1A-α1B- and α1D-ARs in these aortic smooth
muscle cells. Therefore, the presence of the other α1-ARs, and the potential for dimerization with
these receptors, does not alter the intracellular expression of the α1D-AR. Despite the
predominant intracellular localization in vascular smooth muscle cells, the α1D-AR remained
signaling competent and mediated the phenylephrine-induced increases in intracellular calcium. The
α1D-AR also was coupled to the generation of reactive oxygen species in smooth muscle cells.
There is evidence from heterologous systems that the α1D-AR heterodimerizes with the β2-AR and
that desensitization of the β2-AR results in α1D-AR desensitization. In the rat aorta, desensitization
of the β2-AR had no effect on contractile responses mediated by the α1D-AR.
Conclusion: Our results suggest that the dimerization of the α1D-AR with other ARs does not
alter the cellular expression or functional response characteristics of the α1D-AR.
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Background
The α1-ARs are members of the class I of the G-protein
coupled receptors (GPCR) superfamily [1,2]. Three α1-
ARs, α1A-AR, α1B-AR and α1D-AR have been cloned and
characterized [1,3,4]. These receptors mediate responses
to epinephrine and norepinephrine thus making a vital
contribution to the control of blood flow and systemic
arterial blood pressure. Abnormalities in the regulation of
the α1-ARs may contribute to the development of hyper-
tension and heart failure [5-8].
It is well known that the localization and trafficking prop-
erties of a receptor can modulate its physiological func-
tion [9]. Results from heterologous expression systems
have demonstrated that the α1B-AR is localized on the cell
surface, as expected for a GPCR, while the α1A-AR is local-
ized not only on the cell but also in intracellular compart-
ments [10,11]. In contrast, we have shown that the α. In
contrast, we have shown that the α1D-AR is localized intra-
cellularly [11,12]. These results of nonconical cellular
locatization are consistent with emerging data that show
specific GPCR families can be localized not only to intra-
cellular sites but also on the nuclear membrane [13].
In recent years, the concept of receptor dimerization has
brought a new perspective to GPCR function [14-16]. Pre-
vious studies reported that the α1D-AR interacts with the
α-AR interacts with the α1B-AR and the β2-AR [17] result-
ing in the cell surface expression of the α1D-AR. This has
lead to the suggestion that these receptors are capable of
heterodimerization [17-20]. These observations have
been made in heterologous systems. However, the role of
dimerization in the regulation of cells that natively
express all three receptors such as vascular smooth muscle
cells has not been well studied. This is due in part to the
difficulty of tranfecting smooth muscle cells. To overcome
this obstacle, we developed a recombinant adenovirus for
the efficient expression of the human α1D-AR. We show
that despite the presence of the other α1-AR family mem-
bers, the α1D-AR is expressed mainly in intracellular com-
partments. We further show that while receptor
dimerization may occur, it does not appear to alter the
functional properties of the α1D-AR.
Results
Cellular localization
An adenoviral vector was constructed to drive the efficient
expression of a GFP-labeled α1D-AR. Infection of aortic
smooth muscle cells with virus expressing the α1D-AR/
GFP resulted in approximately 80% receptor transfec-
tional efficiency (not shown) demonstrating that adeno-
virus can be useful in cells that have been traditionally
difficult to transfect with the α1-ARs. Following viral infec-
tion, the α1D-AR/GFP was detected in intracellular com-
partments of aortic smooth muscle cells (Figure 1A). A
similar pattern of vascular smooth muscle intracellular
expression was seen with immunocytochemistry studies
using an α1D-AR selective antibody (Figure 1B). These
localization results in smooth muscle cells are similar to
our previous findings in HEK 293 cells transfected with an
α1D-AR/GFP expression plasmid or immunohistochemis-
try studies in fibroblasts stably transfected with the α1D-
AR [12,21]. Recently, it was proposed that the α1D-AR can
dimerize with the α-AR can dimerize with the α1B-AR pro-
moting its cell surface expression [19]. Our results would
argue that the presence of other ARs, particularly the α1B-
AR, does not alter α1D-AR localization in vascular smooth
muscle cells. To further substantiate that the presence of
the  α1B-AR does not affect α1D-AR localization, we
infected fibroblasts that stably express the α1B-AR with the
α-AR with the α-AR with the α-AR with the α1D-AR/GFP
adenoviral construct (Figure 1C). Despite expression in a
cell expressing the α1B-AR at high levels, α1D-AR was none-
theless expressed in intracellular compartments (Figure
1C). These data argue that the α1B-AR does not alter the
cellular localization of the α1D-AR.
It is possible, however, that in these cultured smooth mus-
cle cells the α1B-AR and/or α1A-AR are not expressed. To
examine this possibility we used RT-PCR to assess mes-
sage expression. The results of these experiments are
shown in figure 2A. A very prominent PCR-product corre-
sponding to the α1B-AR was detected in aortic smooth
muscle cells. We were also able to detect an α1A- AR tran-
script. A very faint product corresponding to the α- AR
The Cellular Localization of the α1D-AR in Human Aortic  Smooth Muscle Cells Figure 1
The Cellular Localization of the α1D-AR in Human 
Aortic Smooth Muscle Cells. Panel A; Human aortic 
smooth muscle cells were infected with an α1D-AR/GFP 
expressing virus. Panel B; Immunofluorescence localization of 
the α1D-AR in human aortic smooth muscle cells. Panel C; 
Rat 1 Fibroblasts were infected with an α1D-AR/GFP 
expressing virus. Adenoviral infection and immunostaining 
were carried out as described in Methods. Localization pat-
terns were visualized with laser scanning confocal micros-
copy.Journal of Molecular Signaling 2008, 3:6 http://www.jmolecularsignaling.com/content/3/1/6
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transcript. A very faint product corresponding to the α1D-
AR was also observed. Minute levels of tissue expression
are typical for this receptor. A series of antibodies directed
against each of the α1-ARs was used to determine the cel-
lular localization of these receptors (Figure 2B). As has
been shown by previous work the α). As has been shown
by previous work the α1A- AR is expressed both intracellu-
larly as well as on the cell surface while the α1B-AR is
expressed predominately on the cell membrane. What is
also apparent from comparing figures 1A–C and figure 2B
is that the expression pattern of the α is that the expres-
sion pattern of the α1D- AR is markedly different from that
of either the α- AR is markedly different from that of either
the α1A- or α- or α1B-ARs. Therefore, in a mammalian cell
where both the α1A- and α- and α1B-AR are natively
expressed (as opposed to being transfected) the α1D-AR is
nonetheless expressed intracellularly. Further, the data
argue that while dimerization may occur in smooth mus-
cle cells, it does not alter the localization of the α1D-AR.
Effects on intracellular calcium
In aortic smooth muscle cells phenylephrine produced a
dose-dependent and statistically significant increase in
intracellular calcium (see data for 25 uM presented in Fig-
ure 3). This increase was antagonized by 1 nM of the non-
selective α1-AR blocker prazosin or 30 nM of the highly
selective α1D-AR antagonist BMY 7378. To substantiate
the selectivity of this dose of BMY 7378 we measured phe-
nylephrine-induced increases in intracellular calcium lev-
els in fibroblasts stably transfected with either the α1A-AR,
α1B-AR or the α1D-AR. Despite pretreatment with 30 nM
BMY 7378, phenylephrine maintained the ability to pro-
mote increases in intracellular calcium in the α1A-AR or
α1B-AR expressing lines of fibroblasts (Figure 4). In con-
trast, BMY 7378 blocked the phenylephrine-induced
increases in intracellular calcium in fibroblasts stably
transfected with the α1D-AR (Figure 4). Therefore, BMY
7378 at 30 nM, the concentration used in the vascular
Effect of Phenylephrine on Intracellular Calcium Levels in  Human Aortic Smooth Muscle Cells Figure 3
Effect of Phenylephrine on Intracellular Calcium Lev-
els in Human Aortic Smooth Muscle Cells. Human aor-
tic smooth muscle cells were loaded with Calcium Green 1 
AM for 1 hr. The ability of 25 uM phenylephrine to increase 
intracellular calcium was studied alone and following treat-
ment with either 1 nM prazosin or 30 nM BMY 7378. Experi-
ments were carried out as described in Methods. The results 
of a typical imaging study are presented along with a graphical 
summary of the statistical analysis of four independent exper-
iments. Data were analyzed by a one-way ANOVA followed 
by post hoc testing. * Indicates a statistically significant differ-
ence from the untreated control.
Panel A; RT-PCR Measurement of α1-AR mRNA in Human  Aortic Smooth Muscle cells Figure 2
Panel A; RT-PCR Measurement of α1-AR mRNA in Human 
Aortic Smooth Muscle cells. Panel B; Immunolocalization of 
the α1-ARs in human aortic smooth muscle cells. Reverse 
transcription and PCR analysis and immunocytochemistry 
were performed as described in Methods.Journal of Molecular Signaling 2008, 3:6 http://www.jmolecularsignaling.com/content/3/1/6
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Effect of Phenylephrine on Intracellular Calcium Levels in Stably Transfected Rat 1 Fibroblasts Figure 4
Effect of Phenylephrine on Intracellular Calcium Levels in Stably Transfected Rat 1 Fibroblasts. Rat 1 Fibroblasts, 
stably transfected with each of the α1-ARs, were loaded with Calcium Green 1 AM for 1 hr. The ability of 10 uM phenylephrine 
to increase intracellular calcium was studied alone and following treatment with either 1 nM prazosin or 30 nM BMY 7378. 
Experiments were carried out as described in Methods. The results of a typical imaging study are presented along with a graph-
ical summary of the statistical analysis of four independent experiments. Data were analyzed by a one-way ANOVA followed 
by post hoc testing. * Indicates a statistically significant difference from the untreated control.Journal of Molecular Signaling 2008, 3:6 http://www.jmolecularsignaling.com/content/3/1/6
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smooth muscle cells (see above), can selectively block the
α1D-AR. These data support the conclusion that the recep-
tor that mediates increases in intracellular calcium in aor-
tic smooth muscle cells is the α1D-AR.
Effects on reactive oxygen species
This type of specificity of coupling was also observed
using a novel functional response to activation of the α1-
AR-namely the generation of reaction oxygen species. In
human aortic smooth muscle cells, phenylephrine pro-
duced a rapid, dose-dependent and statistically significant
increase in the level reactive oxygen species (Figure 5).
While we present the data with 10 uM, we could see statis-
tically significant increases in ROS at 1 uM phenylephrine.
This increase was blocked by 1 nM prazosin or 30 nM
BMY 7378. Therefore, it is the α1D-AR that mediates
increases in reactive oxygen species in these vascular
smooth muscle cells.
Effects on smooth muscle contraction
Recent data from heterologous systems have suggested
that the interaction between the α1D-AR and other G-pro-
tein coupled receptors alters the pharmacologic properties
of the α1D-AR [17,19]. Our results from vascular smooth
muscle cells that naturally express all three receptors indi-
cate that functional responses from a receptor with α1D-
AR characteristics can be detected.
To assess the relevance of the interaction between the α1D-
AR and the other ARs in an intact blood vessel system, we
studied contractile responses in the rat aorta. In previous
work we have shown that the contractions of the rat aorta
are mediated by the α1D-AR [22]. In addition to potential
dimerization among the α1-ARs, there is evidence of het-
erodimerization between the α1D-AR and β2-AR. Studies
in heterologous systems also show that desensitization of
the β2-AR with albuterol promotes the internalization and
desensitization of the α1D-AR [17]. We assessed responses
in the rat aorta following a 12 hr exposure to albuterol.
After this incubation period, the responses to albuterol
were significantly decreased when compared to vehicle
treated aorta (Figure 6). This indicates a desensitization of
the β2-AR mediated response. The phenylephrine log dose
response curves were the same in control and albuterol
desensitized aorta. Therefore, desensitization of β2-AR
does not lead to desensitization of the α1D-AR.
Discussion
Previous work from our laboratory has shown that in het-
erologous systems the α1D-AR localizes intracellularly and
does not undergo agonist-mediated internalization or
desensitization [11,12,21]. Due in part to problems with
transfection, it has been difficult to determine if this type
of expression pattern occurs in cells that natively express
the α1D-AR along with the other α1-AR family members.
To facilitate its efficient expression, we developed an ade-
noviral vector expressing the human α1D-AR fused with
the GFP. We then used the vector to infect human aortic
smooth muscle cells. RT-PCR analysis showed that these
cells express all three α1-ARs (Figure 2). The rank order of
mRNA expression was α1B-AR>  α1A-AR>>α1D-AR. This
type of expression pattern is typical for the α1-ARs. Fol-
lowing infection of aortic smooth muscle cells we
observed that the α1D-AR was localized to intracellular
compartments (Figure 1A). An intracellular localization
pattern was also observed when aortic smooth muscle
cells were immunostained with an α1D-AR antibody (Fig-
ure 1B). Therefore, while dimerization between the α1D-
AR and the other α1-ARs may occur in aortic smooth mus-
cle cells, this does not alter the cellular localization of the
α1D-AR.
If the α1D-AR forms heterodimers with the other α1-ARs,
then it is possible that these complexes exhibit properties
different from the α1D-AR alone [17,19]. We examined
this possibility using the selective antagonist BMY 7378.
In previous work we calculated that at 30 nM over 90 % of
the α1D-ARs would be occupied by BMY 7378 while less
than 10 % of either the α1A-AR or the α1B-AR would be
Effect of Phenylephrine on the Levels of Reactive Oxygen  Species Levels in Human Aortic Smooth Muscle Cells Figure 5
Effect of Phenylephrine on the Levels of Reactive 
Oxygen Species Levels in Human Aortic Smooth 
Muscle Cells. Human aortic smooth muscle cells were 
loaded with Mitotracker ROS for 20 min. The ability of 10 
uM phenylephrine to increase the levels of reactive oxygen 
species was studied alone and following treatment with 
either 1 nM prazosin or 30 nM BMY 7378. Experiments were 
carried out as described in Methods. The results of a typical 
imaging study are presented along with a graphical summary 
of the statistical analysis of four independent experiments. 
Data were analyzed by a one-way ANOVA followed by post 
hoc testing. * Indicates a statistically significant difference 
from the untreated control.Journal of Molecular Signaling 2008, 3:6 http://www.jmolecularsignaling.com/content/3/1/6
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occupied by this antagonist [22]. Therefore, at this con-
centration BMY 7378 would be anticipated to be highly
selective for the α1D-AR. This was substantiated in fibrob-
lasts stably transfected with each of the α1-ARs. In these
fibroblast cell lines phenylephrine treatment produced a
significant increase in intracellular calcium. However,
only in fibroblasts expressing the α1D-AR was BMY 7378
capable of antagonizing the calcium response to phenyle-
phrine, indicating that BMY 7378 is selective for the α1D-
AR (Figure 4). The phenylephrine-mediated increases in
intracellular calcium in aortic smooth muscle cells were
also blocked by this dose of BMY 7378 (Figure 3). In a
similar fashion, we demonstrated that the generation of
reactive oxygen species in aortic smooth muscle cells was
antagonized by 30 nM BMY 7378 (Figure 5). There is no
evidence that BMY 7378 at this concentration can block
either the α1A- or the α1B-AR. Therefore the antagonism
seen with BMY 7378 indicates that the observed increases
in intracellular calcium and reactive oxygen species are
mediated by a receptor of α1D-AR character. In aggregate,
the data suggest that while heterodimerization may occur,
it does not appear to alter the pharmacologic properties of
the α1D-AR. We know that both increases in intracellular
calcium and elevations in ROS are mediated by the α1D-
AR. What we do not know is if the intracellularly
expressed α1D-AR is signaling competent and responsible
for these effects or whether it is a small population of cell
surface expressed receptors. If signaling does indeed ema-
nate from the intracellular α1D-AR, then there has to be a
pathway that would allow agonist access to these recep-
tors.
In addition to dimerization within the α1-AR family, there
is also evidence that the α1D-AR can form dimers with the
β2-AR. Studies in expression systems have shown that not
only does the β2-AR promote the cell surface expression of
the  α1D-AR but that desensitization of the β2-AR also
desensitized the α1D-AR response. We wished to deter-
mine if this type of activity could be obtained in a func-
tional system that natively expresses these receptors
without resorting to overexpression of cloned receptors in
a model cell system. The contractile responses of phenyle-
phrine in the rat aorta are due to interactions at the α1D-
AR (see for example, Piascik et al. [22]). Therefore, we
assessed potential β2-AR/α1D-AR interactions using this
blood vessel. Overnight treatment of blood vessels with
albuterol caused desensitization of the β2-AR as shown by
diminished vasodilatory responses to this agent (Figure
6A). However, desensitization of the β2-AR did not cause
a rightward shift of the phenylephrine dose response
curve (see Figure 6B). Therefore, desensitization of the β2-
AR does not alter contractile responses to the α1D-AR.
These results show that cross desensitization between β2-
AR and the α1D-AR does not occur in an intact, responding
segment of vascular smooth muscle.
Conclusion
In summary, adenoviral vectors expressing the α1-ARs are
a novel and efficient tool to investigate properties of these
receptors in native cells. These vectors were used to show
that in human smooth muscle cells expressing all three
α1-ARs, the α1D-AR is localized in intracellular compart-
ments. Therefore, despite recent reports of heterodimeri-
zation between the α1-ARs, in a human vascular smooth
muscle cell line, the α1D-AR is still expressed intracellu-
larly. Indeed none of the data we obtained in this work
support the idea of α1D-AR heterodimerization. Using
three independent measures (calcium levels, generation
Effect of the Albuterol Pretreatment of Phenylephrine- Induced Contraction of the Rat Aorta Figure 6
Effect of the Albuterol Pretreatment of Phenyle-
phrine-Induced Contraction of the Rat Aorta. Panel A; 
Log-dose response curves of the ability of albuterol to relax 
the rat aorta. The aorta was contracted with KCl and the 
albuterol responses were assessed in control blood vessels 
and in those vessels desensitized by incubation with 1 uM 
albuterol for 12 hr. Data are the mean +/- the SEM of 10 
(control) or 13 (desensitized) experiments. Panel B; Log-
dose response curves for the ability of phenylephrine to 
induce contraction of the aorta following desensitization with 
albuterol. Data are the mean +/- the SEM of 6 independent 
experiments.Journal of Molecular Signaling 2008, 3:6 http://www.jmolecularsignaling.com/content/3/1/6
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of reactive oxygen or vascular smooth muscle contraction)
we also could not detect any evidence of altered pharma-
cologic properties of the α1D-AR.
Methods
Cell culture conditions
Human aortic smooth muscle cells were obtained from
Cascade Biologics (Portland, OR) and grown in Medium
231 supplemented with smooth muscle growth supple-
ment until they become confluent (Cascade Biologics,
Portland, OR). Stably transfected Rat 1 fibroblast lines
expressing each of the α1-AR subtypes were maintained in
Dulbecco's modified Eagle's medium (Cellgro, Herdon,
VA) supplemented with 10% fetal bovine serum and a 1%
antibiotic/antimycotic cocktail (Invitrogen, Carlsbad,
CA). All cells were grown in T75 flasks in a 37°C cell cul-
ture incubator with a humidified atmosphere (95% air
and 5% CO2) and were fed every 2 to 3 days. After reach-
ing confluence the cells were plated on plain untreated
coverslips in 35 mm tissue culture dishes.
Construction of recombinant adenoviruses expressing the 
α1-ARs
A vector expressing the human α1D-AR coupled to the
green fluorescent protein (α1D-AR/GFP) was provided by
Dr. Gozoh Tsujimoto [23,24]. This vector was digested
with EcoRI and XbaI enzymes and cloned into the pCI
expression vector (Promega. Madison, WI). pCI was
digested with BglII and ClaI. This fragment included the
CMV I.E. promoter, the α1D-AR/GFP and the SV40 late
poly (A). The BglII and ClaI fragment was cloned into the
adenovirus recombination vector pAdLink. pAdLink and
the wild type adenovirus vector, dl327, were linearized
with NheI and ClaI respectively. Homologous recombina-
tion occurred by co-transfecting linearized pAdLink and
the wild type adenovirus vector into HEK 293 cells. Posi-
tive plaques appeared 10 to 14 days after recombination
and were then amplified. Plaques were purified by serial
dilutions of a positive plaque (usually from 10-3 to 10-12)
in 96 well plates using HEK 293 cells. After plaque purifi-
cation, samples of viral DNA were analyzed for wild type
virus contamination by PCR [25]. Once a purified adeno-
virus was obtained, the plaque was amplified for large-
scale production. Fifty 150 mm dishes of HEK 293 cells
were used for amplification of adenovirus which was then
purified using double cesium gradients. Adenovirus was
tittered using the Adeno-X™ Rapid Titer Kit from BD Bio-
sciences (Palo Alto, CA).
Infection of cells with recombinant adenovirus
Human aortic smooth muscle cells or Rat 1 fibroblasts were
grown on glass coverslips. Two hours prior to infection,
cells were placed in serum free medium and infected with
adenovirus. Twenty four hours after infection the medium
was changed and the virus free incubation was allowed to
proceed for an additional 24 hours. Cells expressing the
GFP labeled α1D-AR were fixed with 3.7% Formaldehyde
in PBS for 10 mins. Cells were then mounted on slides
with Vectashield (Vector Labs, Burlingame, CA). Cells
were visualized using a Leica TCS SP 5 AOBS confocal
microscope with a Plan-Apo 64X oil immersion objective
lens (Leica, Wetzlar, Germany) using Leica TCS NT ver-
sion 2.5 software. Images were transferred to a computer
for reduction with Adobe Photoshop version 6.0 (Adobe
Systems, Mountain View, CA).
Immunocytochemistry
Human aortic smooth muscle cells or grown on glass
cover slips, were washed in PBS and fixed with 3.7% For-
maldehyde in PBS for 10 min. Cells were then washed
with .05% BSA in PBS and permeabilized with 0.1% Tri-
ton in PBS for 5 min. After permeabilization, the cells
were washed and blocked with 10% lamb serum for 1
hour at room temperature. After washing polyclonal anti-
bodies (Affinity Bioreagents, Golden, CO) against each of
the α1-ARs, diluted 1:100 in 1% BSA in PBS, was added
and incubated overnight at 4°C. Following this incuba-
tion, the cells were washed with .05% BSA in PBS and a
Texas Red secondary antibody (Abcam, Cambridge MA),
diluted 1:500 in PBS, was added and incubated in the dark
at room temperature for 1 hr. Cells were washed with PBS
and mounted on glass slides with Vectashield (Vector Lab-
oratories, Burlingame, CA). Cells were visualized with a
confocal microscope as described above.
RT-PCR
Total RNA from HASMCs was isolated and purified with
the ChargeSwitch Total RNA kit from Invitrogen
(Carlsbad, CA), and 0.5 μg samples were reverse tran-
scribed at 45°C for one hour using Cloned Avian Myelob-
lastosis Virus (AMV) Reverse Transcriptase and
Oligo(dT)20 primer (Invitrogen, Carlsbad, CA). After heat-
ing at 85°C for 5 min. to terminate the reaction, cDNA
samples were stored at -20°C until used. Negative con-
trols for the presence of genomic DNA were performed by
replacing the reverse transcriptase enzyme with Taq DNA
polymerase.
For PCR, primers were synthesized by Invitrogen based on
those used by Esbenshade et al. [26] to detect and distin-
guish specific human AR subtypes. Sequences of the prim-
ers were as follows: α1A, 5'-ATGCTCCAGCCAAGAGTTCA-
3' (sense, annealing to bases 1417–1437) and 5'-TCCAA-
GAAGAGCTGGCCTTC-3' (antisense, bases 1898–1918);
α1B, 5'-CTGTGCGCCATCTCCATCGATCGCTAC-3'
(sense, bases 406–432) and 5'-ATGAAGAAGGG-
TAGCCAGCACAAGATGAA-3' (antisense, bases 907–
935); α1D, 5'-CTCTGCACCATCTCCGTGGACCGGTAC-3'
(sense, bases 563–589) and 5'-AAAGAAGAAAGGGAAC-
CAGCAGAGCACGAA-3' (antisense, bases 1073–1102).Journal of Molecular Signaling 2008, 3:6 http://www.jmolecularsignaling.com/content/3/1/6
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The receptor specific primers target sequences within the
third intracellular loop (sense) and the carboxy terminus
(antisense). Primers for β-actin were included as a positive
control (RT-PCR Primer and Control Set, Invitrogen). The
predicted sizes of the amplified human β-actin, α1A-, α1B-
, and α1D-AR PCR products were 353, 502, 530, and 540
bp, respectively.
PCR was carried out with Platinum Taq DNA polymerase
(Invitrogen) in a PCR Express (Hybaid Ltd., United King-
dom) thermal cycler. The amplification reactions,
repeated for 35 cycles, consisted of denaturation at 94°C
for 1 minute, annealing at 55°C for 30 seconds, and
extension at 72°C for 1 minute. PCR products were run
on a 1.4% agarose gel.
Determination of intracellular calcium
Human aortic smooth muscle cells were loaded for 1 hour
with 5:M Calcium Green ™ 1 AM (Molecular Probes,
Eugene, OR). In certain experiments, Rat 1 fibroblasts
were also loaded with the Calcium Green. Cells were then
washed twice with serum containing medium and visual-
ized with an inverted microscope with a Xe arc lamp with
a Plan-Apo 60X oil immersion objective and an excitation
filter of 480/15 nm and an emission filter of 535/20 nm.
Images were taken using a CoolSnap HQ camera. Indica-
tor dye-loaded cells underwent several drug treatments.
Human aortic smooth muscle cells were pre-treated with
vehicle, 1 nM prazosin or 30 nM BMY 7378 for 20 min-
utes, followed by 25 :M phenylephrine. Stably transfected
fibroblasts were challenged with 10 :M phenylephrine. A
higher phenylephrine concentration was required in
smooth muscle to observe an equivalent increase in the
calcium signal. Images from calcium measurements were
processed using Metamorph software (Molecular Devices,
Sunnyvale, CA). In the analysis, the nucleus was masked
leaving the cytoplasm. The mean intensity of the cyto-
plasm was then taken for each cell. Images were prepared
using Adobe Photoshop version 6.0 (Adobe Systems,
Mountain View, CA). lmaging data were analyzed by one-
way analysis of variance with Tukey's post-hoc test using
GraphPad Prism version 3.00 for Windows (GraphPad
Software, San Diego, CA). In all figures, the data are
expressed as the mean and standard error of the mean
(S.E.). A value of P < 0.05 was considered statistically sig-
nificant.
Reactive oxygen species
The generation of reactive oxygen species was measured
using Mitotracker ROS (Invitrogen, Carlsbad, CA) diluted
in DMSO. Human aortic smooth muscle cells, attached to
glass coverslips, were incubated for 20 min at 37° with 5
nM Mitotracker ROS diluted in Serum Free Medium. Cells
were washed twice with medium and fresh medium
applied. After this time 10 μM phenylephrine was added
and incubated with the cells for 20 min. Preliminary stud-
ies established this time as that optimal to record a signif-
icant increase in ROS levels. In certain experiments, cells
were pretreated with 1 nM prazosin or 30 nM BMY 7378
prior to the addition of phenylephrine. After agonist incu-
bation, the cells were fixed with 1.0% formaldehyde in
PBS for 10 min and washed with PBS. Cells were mounted
on slides with Vectashield (Vector Laboratories, Burlin-
game, CA). Cells were imaged by confocal microscopy as
described above. Images were processed using Meta-
morph software (Molecular Devices, Sunnyvale, CA).
Images were prepared using Adobe Photoshop version 6.0
(Adobe Systems, Mountain View, CA). lmaging data were
analyzed by one-way analysis of variance with Tukey's
post-hoc test using GraphPad Prism version 3.00 for Win-
dows (GraphPad Software, San Diego, CA). In all figures,
the data are expressed as the mean and standard error of
the mean (S.E.). A value of P < 0.05 was considered statis-
tically significant.
Assessment of aortic contractile function
All animal protocols were reviewed and approved by the
University of Kentucky Institutional Animal Care and Use
Committee. Isolated blood vessels were prepared by tech-
niques routinely used in our laboratory [21,22,27,28].
Aorta were removed from male Sprague-Dawley rats,
cleaned of adventitia and extraneous tissue and then seg-
mented into 1–2 mm rings. Following isolation, aortic
rings were placed in a 37EC cell culture incubator and
treated for 12 hr with 1 :M albuterol, a selective β2-AR ago-
nist or a vehicle control. After this period, rings were
placed in the tissue baths for the assessment of contractile
activity. The water-jacketed muscle baths were filled with
physiologic saline solution maintained at 37°C with con-
stant oxygenation (95% O2, 5% CO2, pH 7.4) and under
a passive force of 2.0 grams. Previous studies have shown
that this passive force gives optimal responses. Aortic rings
were contracted with 25 mM KCl and the ability of
increasing amounts of albuterol to induce aortic relaxa-
tion was measured. Phenylephrine-dose response curves
were also generated in a separate set of aortic rings treated
with albuterol. Changes in the force generation were
recorded using force displacement transducers (Astro-
Med, Inc., Grass Instruments, West Warwick, RI) inter-
faced to a Dell computer. Data were retrieved using Poly-
VIEW version 2.5 and analyzed using GraphPad Prism
version 3.00 for Windows (GraphPad Software, San
Diego, CA).
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